Elevara raises $70M Series A to accelerate RA therapy ELV001 2025

Elevara Medicines has clinched a $70 million Series A financing round, led by Sofinnova Partners with a co-lead from Forbion, and reinforced by the founding investor Monograph Capital. The capital will accelerate the company’s lead program and broaden its inflammatory-disease portfolio, underscoring strong conviction in a novel therapeutic approach. The round also accompanies Elevara’s ongoing collaboration with Teijin Pharma, through which the company gained exclusive global rights to ELV001.

ELV001, a first‑in‑class oral CDK4/6 inhibitor, into its upcoming Phase 2 START-SYNERGY trial and to explore additional chronic inflammatory conditions and women’s health indications. The Phase 2 study plans to enroll about 180 patients who have had an inadequate response to methotrexate and TNF inhibitors, with recruitment anticipated by year-end 2025. This marks a pivotal step in Elevara’s strategy to deliver an add‑on oral therapy capable of complementing existing regimens.

Emma Tinsley (CEO) and Dominique Baeten (CMO), together with a board featuring notable industry participants, signals a disciplined path toward later-stage development. Investors cited the asset’s differentiated profile and the potential to synergize with existing RA therapies as key catalysts for momentum in the coming years.